Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...

Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the treatment of ophthalmic diseases, today announced that clinical ...

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

Sedgwick brand protection has launched the first Australian edition of its Recall Index, which tracks product recalls and regulatory developments across five major industries.

Vir Biotechnology, Inc. (NASDAQ: VIR) has announced the closing of an exclusive worldwide license agreement with Sanofi, strengthening its drug discovery capabilities in oncology and infectious ...

( MENAFN - Jordan Times) AMMAN - The Jordan Chamber of industry said that the industry index, recorded a growth of 1 per cent ...